Setting 
My Cart
Toggle Nav
Close
  • Menu
  • Setting

EZ Cap™ Firefly Luciferase mRNA (5-moUTP)

Catalog No.
R1013
Firefly Luciferase mRNA with Cap 1 structure, modified by 5-moUTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.
Grouped product items
SizePriceStock Qty
100ug (1mg/mL)
$210.00
In stock
1mg (1mg/mL)
$1,136.00
In stock
5x1mg (1mg/mL)
$4,090.00
In stock
For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

EZ Cap™ Firefly Luciferase mRNA (5-moUTP) will express luciferase protein once entering cells, which is initially extracted from firefly Photinus pyralis. This enzyme catalyzes ATP-dependent D-luciferin oxidation and lead to yield chemiluminescence at about 560 nm wavelength. Firefly Luciferase is a frequently used bioluminescent reporter for gene regulation and function study. It is applicable in assays for mRNA delivery, translation efficiency, cell viability and in vivo imaging etc.

EZ Cap™ Firefly Luciferase mRNA (5-moUTP) is provided at a concentration of ~1 mg/ml with Cap1 structure. There are currently two ways to cap mRNA: One is co-transcription method, by adding Cap analogues into the transcription process. The other is enzymatic Capping. After transcription, Cap0 capping is performed by Vaccinia virus Capping Enzyme (VCE), GTP and S-adenosylmethionine (SAM). The Cap0 is then generated into the Cap1 through 2´-O-Methyltransferase and SAM. Cap1 Capping can also be performed by adding VCE, 2´-O-Methyltransferase, GTP and SAM in a one-step process. Cap 1 structure is more ideal for mammalian systems and possess higher transcription efficiency than Cap 0 structure. The addition of 5-moUTP and poly(A) tail suppress RNA-mediated innate immune activation and increase the stability and lifetime of the mRNA in vitro and in vivo. Poly(A) tail also plays an important role in enhancing the efficiency of translation initiation.

Description

mRNA Length 1921 nucleotides
Concentration1 mg/mL
Buffer 1 mM Sodium Citrate, pH 6.4 Storage -40°C or below
General tipsPlease dissolve it on ice and protect from RNase carefully. Avoid repeated freeze/thaw cycles as possible. Don’t vortex. Upon first use, centrifuge the tube softly and aliquot it into several single use portions. Use RNase-free reagents and materials with appropriate RNase-free technique. Don’t add to the media with serum unless mixing with a transfection reagent.
Shipping Conditionship with dry ice.

Product Citation

Quality Control

Quality Control & Datasheet

View current batch:

Related Biological Data

EZ Cap™ Firefly Luciferase mRNA (5-moUTP)

Related Biological Data

EZ Cap™ Firefly Luciferase mRNA (5-moUTP)

Related Biological Data

EZ Cap™ Firefly Luciferase mRNA (5-moUTP)
 

FAQ

1. How do I choose the right RNA product for my research?

It can be based on your experimental goals:

  • For Tracking Transfection and Translation Efficiency: APExBIO Reporter Gene mRNAs (e.g. EGFP, Firefly Luciferase mRNA) are commonly used to track transfection efficiency and protein expression duration; evaluate gene expression and cell viability; study mRNA localization and bio-distribution via in vivo imaging; optimize transfection conditions and validate LNP delivery system.
  • For Gene Editing, Functional Studies and Gene Therapy Research: APExBIO offers various functional protein mRNAs, involving tumor suppressors (e.g. p53, PTEN), cytokines (e.g. IL-12, IL-10), gene-editing tools (e.g. spCas9, Cre Recombinase), gene replacement protein (e.g. EPO), and antigens (e.g. OVA, SARS-CoV-2 Spike).
  • For Sustained Protein Expression: APExBIO Self-amplifying RNA (saRNA) and Circular RNA (circRNA) are recommended for applications requiring prolonged protein expression. saRNA enables lasting and strong protein expression at lower doses, while circRNA has enhanced structural stability and extended expression duration.
2. What are the key advantages of APExBIO mRNA products?
  • Advanced Capping Technology: Utilizes Cap 1 structure (EZ Cap™ Cap) to achieve enhanced translation efficiency and minimizing activation of the host innate immune response. The capping efficiency can reach 90–99%.
  • Diverse Modification Options: Provides a range of modified nucleotides, such as m1Ψ B8049, 5-moUTP B8061 and Cy5-UTP B8333, which reduce immunogenicity, improve mRNA stability, and maximize protein expression levels.
  • Stringent Quality Control: Each batch undergoes rigorous quality assessment including capping efficiency, purity, integrity, and sterility to ensure batch-to-batch consistency.